Product category:
Chromatographs: liquid, ion, gel, HPLC
News Release from: ESA Biosciences
Edited by the Laboratorytalk Editorial
Team on 15 August 2007
New HPLC systems speed drug-metabolism
studies
ESA Biosciences, a Magellan Biosciences company, has launched new HPLC systems designed to help speed drug-metabolism studies and support medicinal chemistry activities
The new HPLC systems have been developed to electrochemically synthesise significant quantities of difficult-to-obtain metabolites from a variety of parent compounds At the systems' core are new, high efficiency, high capacity electrochemical-synthesis cells
This article was originally published on Laboratorytalk on 24 Jul 2008 at 8.00am (UK)
Related stories
Determining low level impurities in APIs
ESA Biosciences has a new technical poster describing how the Corona Cad enables routine measurement of low-nanogram levels of organic impurities in active pharmaceutical ingredients
Free guide to optimised electrochemical detection
ESA Biosciences has published an informative 14-page guide for laboratories interested in gaining the full sensitivity and selectivity benefits from a HPLC electrochemical detection (ECD) system
Since the user can control the systems' oxidation capability to generate specific, desired oxidation products, they have wide utility in a variety of metabolite-generation tasks, alleviating the need to deploy precious medicinal chemistry resources to support drug-metabolism identification, while enhancing the synthesis capabilities of any laboratory.
Assessing metabolic stability and correctly identifying a compound's metabolites using various in vitro and in vivo drug-metabolism assays is a crucial step in determining a compound's suitability for drug development.
However, LC-MS, the typical technique used for metabolism studies, only reports the molecular weight of the metabolites being examined.
Further reading
User group meeting for charged aerosol detection
ESA Biosciences has announced the first UK meeting for users and people interested in the theory, applications and use of its multi-award winning Corona CAD HPLC detector.
Ion analysis through HPLC methodologies: webinar
In today's drug development and manufacturing operations, one of the key analysis steps is the measurement of the amount and type of ion or counter ion present in a particular drug formulation
LCMS cannot easily determine the exact structure of a given metabolite, especially if one or more hydroxylation reactions are involved in the metabolism of the compound.
Irrefutably determining a metabolite's structure often requires synthesis of complicated metabolites by medicinal-chemistry methods - a daunting task, until now, according to ESA director of HPLC marketing, Dr Darwin Asa.
ESA's new electrochemical synthesis systems are an ideal complement to LC-MS for ADME-Tox / DMPK and other drug-metabolism operations, because they can be used to quickly and easily generate large quantities of oxidative metabolites from parent compounds.
Of particular interest to scientists evaluating the metabolic properties and toxicity of potential drugs, these systems mimic much of the oxidation capabilities of cytochrome P450, a key enzyme family that is responsible for metabolising most drugs.
Drug interactions involving the cytochrome p450 system are common, and a major cause of attrition in the drug-development process.
Understanding the metabolites generated by these enzymes is key to understanding a compound's metabolic fate.
ESA has designed two new synthesis cells to suite specific application needs.
The 5150 cell has high capacity and is preferred for low-potential ( less than 500mV) oxidation reactions, while the 5125 cell is recommended for high-potential reactions.
Although smaller in volume, the 5125 cell minimises unwanted over-oxidation reactions.
ESA Biosciences enables answers to pressing applications challenges by applying its expertise in specialty detection and electrochemistry, combined with components, kits, and reagents, for analytical laboratories, commercial diagnostics laboratories, and the clinical point-of-care setting. Request free introductory details about products from ESA Biosciences ...
ESA is a wholly owned subsidiary of Magellan Biosciences.
• ESA Biosciences: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
